Charles Schwab Investment Management Inc Biotechnology

Charles Schwab Investment Management Inc

$521 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$121B	$836 Million 0.16% of portfolio	1,725,281	Q1 2025 Added 3.69%
REGN Regeneron Pharmaceuticals, Inc.	$60.1B	$451 Million 0.09% of portfolio	710,335	Q1 2025 Added 2.09%
ALNY Alnylam Pharmaceuticals, Inc.	$40B	$150 Million 0.03% of portfolio	554,606	Q1 2025 Added 7.91%
EXEL Exelixis, Inc.	$14.3B	$123 Million 0.02% of portfolio	3,321,407	Q1 2025 Added 2.12%
INSM Insmed Inc	$13.9B	$122 Million 0.02% of portfolio	1,602,655	Q1 2025 Added 3.62%
CORT Corcept Therapeutics Inc	$7.4B	$118 Million 0.02% of portfolio	1,031,724	Q1 2025 Reduced 1.89%
HALO Halozyme Therapeutics, Inc.	$8.01B	$112 Million 0.02% of portfolio	1,748,851	Q1 2025 Reduced 1.92%
BMRN Biomarin Pharmaceutical Inc	$11B	$108 Million 0.02% of portfolio	1,532,314	Q1 2025 Added 7.64%
UTHR United Therapeutics Corp	$13.6B	$108 Million 0.02% of portfolio	350,858	Q1 2025 Reduced 5.31%
INCY Incyte Corp	$15.3B	$102 Million 0.02% of portfolio	1,682,029	Q1 2025 Added 2.37%
RPRX Royalty Pharma PLC	$15.8B	$97.2 Million 0.02% of portfolio	3,122,531	Q1 2025 Reduced 0.29%
TECH Bio Techne Corp	$2.08B	$88.6 Million 0.02% of portfolio	1,511,260	Q1 2025 Added 3.11%
JAZZ Jazz Pharmaceuticals PLC	$7.29B	$76.4 Million 0.01% of portfolio	615,717	Q1 2025 Added 0.03%
MRNA Moderna, Inc.	$12.8B	$74.6 Million 0.01% of portfolio	2,629,865	Q1 2025 Added 12.19%
RVMD Revolution Medicines, Inc.	$3.36B	$68.3 Million 0.01% of portfolio	1,930,468	Q1 2025 Reduced 0.03%
BPMC Blueprint Medicines Corp	$7.73B	$53.1 Million 0.01% of portfolio	599,721	Q1 2025 Reduced 0.77%
CYTK Cytokinetics Inc	$3.55B	$52.8 Million 0.01% of portfolio	1,312,857	Q1 2025 Reduced 1.67%
PCVX Vaxcyte, Inc.	$2.12B	$50.3 Million 0.01% of portfolio	1,333,382	Q1 2025 Reduced 0.63%
MDGL Madrigal Pharmaceuticals, Inc.	$5.36B	$50.1 Million 0.01% of portfolio	151,251	Q1 2025 Added 0.34%
TGTX Tg Therapeutics, Inc.	$5.43B	$49.8 Million 0.01% of portfolio	1,262,937	Q1 2025 Reduced 0.52%
ADMA Adma Biologics, Inc.	$3.35B	$48.8 Million 0.01% of portfolio	2,462,005	Q1 2025 Added 0.89%
KRYS Krystal Biotech, Inc.	$3.9B	$45.2 Million 0.01% of portfolio	250,514	Q1 2025 Added 3.02%
BBIO Bridge Bio Pharma, Inc.	$6.79B	$44.3 Million 0.01% of portfolio	1,282,229	Q1 2025 Reduced 1.88%
IONS Ionis Pharmaceuticals Inc	$5.95B	$43.6 Million 0.01% of portfolio	1,443,629	Q1 2025 Reduced 2.55%
SRPT Sarepta Therapeutics, Inc.	$1.19B	$41.2 Million 0.01% of portfolio	646,291	Q1 2025 Added 3.61%
AXSM Axsome Therapeutics, Inc.	$4.4B	$39.3 Million 0.01% of portfolio	337,246	Q1 2025 Added 2.81%
PTCT Ptc Therapeutics, Inc.	$3.32B	$33.7 Million 0.01% of portfolio	662,074	Q1 2025 Reduced 3.45%
CPRX Catalyst Pharmaceuticals, Inc.	$2.15B	$32.2 Million 0.01% of portfolio	1,326,771	Q1 2025 Added 6.4%
RNA Avidity Biosciences, Inc.	$1.75B	$30.2 Million 0.01% of portfolio	1,023,578	Q1 2025 Reduced 0.52%
ROIV Roivant Sciences Ltd.	$8.1B	$28.7 Million 0.01% of portfolio	2,847,625	Q1 2025 Added 1.25%
SMMT Summit Therapeutics Inc.	$5.55B	$28.2 Million 0.01% of portfolio	1,460,717	Q1 2025 Reduced 1.64%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$27.1 Million 0.01% of portfolio	614,886	Q1 2025 Added 1.59%
PTGX Protagonist Therapeutics, Inc	$2.7B	$27 Million 0.01% of portfolio	557,718	Q1 2025 Reduced 3.58%
CRNX Crinetics Pharmaceuticals, Inc.	$1.64B	$25.3 Million 0.0% of portfolio	753,527	Q1 2025 Reduced 0.74%
CRSP Crispr Therapeutics Ag	$5.14B	$24.3 Million 0.0% of portfolio	713,539	Q1 2025 Reduced 1.31%
RYTM Rhythm Pharmaceuticals, Inc.	$4.89B	$23.6 Million 0.0% of portfolio	445,429	Q1 2025 Added 1.18%
AKRO Akero Therapeutics, Inc.	$2.41B	$23.6 Million 0.0% of portfolio	582,254	Q1 2025 Added 7.69%
NUVL Nuvalent, Inc.	$3.47B	$22.5 Million 0.0% of portfolio	317,764	Q1 2025 Reduced 1.79%
BNTX Bio N Tech Se	$27B	$22.2 Million 0.0% of portfolio	243,468	Q1 2025 Added 29.95%
ACLX Arcellx, Inc.	$2.98B	$22.1 Million 0.0% of portfolio	336,949	Q1 2025 Reduced 1.79%
VCYT Veracyte, Inc.	$1.68B	$22 Million 0.0% of portfolio	740,631	Q1 2025 Added 2.73%
RARE Ultragenyx Pharmaceutical Inc.	$1.85B	$21.5 Million 0.0% of portfolio	593,121	Q1 2025 Reduced 3.34%
APLS Apellis Pharmaceuticals, Inc.	$2.19B	$21.1 Million 0.0% of portfolio	964,499	Q1 2025 Reduced 3.24%
FOLD Amicus Therapeutics, Inc.	$1.74B	$20.3 Million 0.0% of portfolio	2,491,080	Q1 2025 Reduced 3.7%
VCEL Vericel Corp	$1.79B	$20.1 Million 0.0% of portfolio	449,615	Q1 2025 Reduced 0.41%
ACAD Acadia Pharmaceuticals Inc	$3.65B	$19.9 Million 0.0% of portfolio	1,200,839	Q1 2025 Reduced 4.04%
SRRK Scholar Rock Holding Corp	$2.06B	$19.8 Million 0.0% of portfolio	617,107	Q1 2025 Reduced 0.85%
NVO Novo Nordisk A S	$151B	$18.1 Million 0.0% of portfolio	261,243	Q1 2025 Added 15.64%
LGND Ligand Pharmaceuticals Inc	$2.24B	$17.8 Million 0.0% of portfolio	168,874	Q1 2025 Reduced 0.91%
IMVT Immunovant, Inc.	$3.55B	$17.2 Million 0.0% of portfolio	626,612	Q1 2025 Added 11.01%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.